The global immunohistochemistry market is projected to reach USD 2.7 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 6.6% during the forecast period. The increasing incidence and prevalence of cancer, technological advancements in IHC, and the availability of reimbursement for IHC tests are the major factors driving the growth of this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939
North America accounted for the largest share of the immunohistochemistryss market in 2019.
In 2019, North America accounted for the largest share of the IHC market. The growth in this regional market can be attributed to the presence of major players operating in the IHC market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.
The global IHC market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), PHC Holding Corporation (Japan), Biocare Medical, LLC. (US), and Merck KGaA (Germany).
In 2019, Roche launched the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody, the first and only in vitro diagnostic ROS1 immunohistochemistry (IHC) assay.
In 2019, Agilent received CE-IVD mark in Europe for its PD-L1 IHC 22C3 pharmDx assay for the identification of head and neck squamous cell carcinoma patients treated with KEYTRUDA.
In 2019, PHC Holding acquired the Anatomical Pathology business (which deals with IHC products) of Thermo Fisher Scientific, Inc.
In 2018, Leica Biosystems launched a new PD-L1 antibody for use on its fully automated BOND IHC and ISH staining platform
Immunohistochemistry (IHC) Market
US EVERY YEAR FOR THEIR
HOME ❯ TOP MARKET REPORTS ❯ IMMUNOHISTOCHEMISTRY (IHC) MARKET
Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents
(Chromogenic Substrates), Kits), Application (Diagnostics (Cancer,
Infectious), Research, Forensic), End User (Hospitals, Diagnostic
Laboratories, Academic) - Global Forecast to 2025
The global immunohistochemistry market is projected to reach USD 2.7 billion by 2025 from USD
1.9 billion in 2020, at a CAGR of 6.6% during the forecast period. The increasing incidence and
prevalence of cancer, technological advancements in IHC, and the availability of reimbursement for
IHC tests are the major factors driving the growth of this market.
COVID-19 impact on the global IHC market
Globally, the COVID-19 outbreak has impacted every aspect of the diagnostic industry, including IHC
testing. In the last few months, the number of patient visits to hospitals has reduced significantly,
despite emergency OPD and laboratory services being available in hospitals.
After commencing cancer surgeries or any other surgeries, surgeons run an IHC test/assay to decide
the best treatment for patients. However, due to lockdowns in Q1 & Q2 2020 in many countries, the
number of elective surgeries and diagnostic tests has significantly reduced. As a result, the number
of IHC tests has reduced. This has significantly reduced the sales of IHC products in Q1 2020 and, to
some extent, in Q2 2020.
Following are some of the government initiatives to delay screening or diagnostic tests for cancer:
In March 2020, the Welsh government and the Scottish government suspended screening
programs for breast, cervical, and bowel cancer.
In the US, the Centers for Medicare & Medicaid Services classified screening as a low-priority
service and suggested healthcare organizations to consider postponing screenings.
The interim Chief Medical Officer of S